The AI Vendor Draft — How Big Pharma Picked Its AI Partners | The Pharma Closeout Special Report

Jun 11, 2026 | Takeda Zasocitinib Beats Sotyktu in Head-to-Head Phase 3; Summit Pulls $500M Offering

Zasocitinib hits 35% complete skin clearance at week 16,topping Sotyktu by more than 2.5x in Takeda's head-to-head Phase 3. Plus: Novartis validates its $12B Avidity AOC platform in FSHD, Summit withdraws $500M offering, and Genentech reshapes its research organization. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, zasocitinib, Takeda, Sotyktu, deucravacitinib, Bristol Myers Squibb, TYK2, plaque psoriasis, PASI 100, Novartis, Avidity Biosciences, AOC, muscular dystrophy, FSHD, SummitTherapeutics, ivonescimab, Kardigan, IPO, J&J, nipocalimab, Imaavy, wAIHA, Genentech, Roche, Vishva Dixit, Camurus, Oclaiz, acromegaly, CRL, Sensorion, Regeneron, hearing loss, Ethyreal, thyroid eye disease, Teva, Astellas, Xtandi, BMS

Jun 10, 2026 | Parabilis Sets Record $670M Biotech IPO; Sanofi Halts Riliprubart Phase 3

Parabilis Medicines prices the largest-ever venture-backed biotech IPO at $670M as 12 startups top $4.1B in 2026. Sanofi stops MOBILIZE Phase 3 for riliprubart in CIDP. TG Therapeutics surges on Briumvi myasthenia gravis data. AstraZeneca's oral GLP-1 elecoglipron hits 11.8% weight loss. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Parabilis Medicines, biotech IPO, zolucatetide, TG Therapeutics, Briumvi, ublituximab, myasthenia gravis, Sanofi, riliprubart, CIDP, complement inhibitor, AstraZeneca, elecoglipron, GLP-1, oral obesity, Novartis, Orionis Biosciences, molecular glue, Beren Therapeutics, adrabetadex, Niemann-Pick disease, SonoThera, Ethyreal, City Therapeutics, Shattuck Labs, Treeline Biosciences, COINS Act, Pfizer, Lilly, Moderna

ADA 2026 Special: The full recap

The Pharma Closeout's full recap of the American Diabetes Association's 86th Scientific Sessions (New Orleans,June 5-8, 2026) - the meeting that ended the A1C-only era and reset what obesity medicine can do. Hosts Alex Mercer and Maya Patel walk every major readout, with the commercial read on each. Visit us at www.thepharmacloseout.com ADA 2026, American DiabetesAssociation, diabetes, obesity, GLP-1, retatrutide, orforglipron, tirzepatide, semaglutide, CagriSema, survodutide, MASH, type 1 diabetes, tegoprubart,teplizumab, Dexcom, CGM, automated insulin delivery, Eli Lilly, Novo Nordisk, Boehringer Ingelheim, AstraZeneca, Roche, Standards of Care, weight loss drugs,endocrinology, pharma, biotech, clinical trials

The AI Vendor Draft — How Big Pharma Picked Its AI Partners | The Pharma Closeout Special Report

In about six weeks this spring, four of the biggest names in pharma each picked an AI partner — Bristol Myers Squibb chose Anthropic's Claude for 30,000+ employees, Merck signed with Google Cloud for up to $1B, Novo Nordisk went with OpenAI, and Eli Lilly built what NVIDIA calls the industry's most powerful AI supercomputer. A Pharma Closeout Special Report, fact-checked against the primary company and FDA releases, on what they actually bought — and who's likely to be proven right. Visit us at www.thepharmacloseout.com pharma, pharmaceutical, AI, agentic AI, artificialintelligence, drug development, biotech, FDA, healthcare, pharma podcast, ThePharma Closeout, Anthropic, Claude, OpenAI, Google Cloud, Gemini, NVIDIA,Bristol Myers Squibb, Merck, Novo Nordisk, Eli Lilly, AstraZeneca, Sanofi,Pfizer, digital health

Jun 07, 2026 | Alnylam's $2B AI-RNA Deal with Inceptive; Lundbeck Bocunebart Migraine Data

Alnylam commits up to $2B to Inceptive Nucleics forAI-driven RNAi drug discovery — $30M upfront, milestone-heavy structure. Lundbeck's bocunebart hits Phase IIb primary endpoint with 1.38-day treatmentdifference in refractory migraine. Plus Otsuka Voyxact IgAN data, Replimune's third RP1 submission, the Supreme Court's skinny label ruling, and Biogen's salanersen Breakthrough Therapy Designation.